

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1	Web Page for STN Seminar Schedule - N. America	
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 33	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 34	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN	Welcome Banner and News Items	
NEWS IPC8	For general information regarding STN implementation of IPC 8	

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:14:28 ON 06 JUN 2007

FILE 'REGISTRY' ENTERED AT 11:14:43 ON 06 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2007 HIGHEST RN 936615-27-9
DICTIONARY FILE UPDATES: 5 JUN 2007 HIGHEST RN 936615-27-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10-562128genA.str
```



```

chain nodes :
11 12 13 14 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
2-16 7-20 8-11 11-12 11-18 12-13 13-14 14-15 14-19 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
2-16 5-7 6-10 7-8 7-20 8-9 9-10 11-12 11-18 12-13 13-14 14-15 14-19
16-17


```

exact bonds :
8-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 11:16:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 227 TO ITERATE

100.0% PROCESSED 227 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3637 TO 5443
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 11:17:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4076 TO ITERATE

100.0% PROCESSED 4076 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01


L3 7 SEA SSS FUL L1

=> d scan

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Serine, N-[[5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (9CI)

MF C35 H31 F N4 O8


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[(7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinoliny]carbonyl]-, ethyl ester (9CI)
MF C20 H26 F N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[(7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinoliny]carbonyl]-, 1,1-dimethylethyl ester (9CI)
MF C25 H34 F N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI)
 MF C19 H24 F N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI)
 MF C18 H22 F N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI)
 MF C21 H26 F N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Glycine, N-[(1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl] - (9CI)
 MF C17 H20 F N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	174.80	175.01

FILE 'CAPLUS' ENTERED AT 11:18:55 ON 06 JUN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jun 2007 VOL 146 ISS 24
 FILE LAST UPDATED: 5 Jun 2007 (20070605/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 abs ibib hitstr

MISSING OPERATOR L3 ABS

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s 13 1-7 abs ibib hitstr

MISSING OPERATOR L3 1-7

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> file caplu

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

2.82

177.83

FILE 'CAPLUS' ENTERED AT 11:22:34 ON 06 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jun 2007 VOL 146 ISS 24

FILE LAST UPDATED: 5 Jun 2007 (20070605/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 7 L3

=> d 14 abs ibib hitstr

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Process for producing compds. I [X = CR7, N; Y = CR6, N; R2 = (un)substituted alkyl, cycloalkyl, aryl, etc.; R3 = halo, alkyl, O-alkyl; R4 = (un)substituted cycloalkyl, non aromatic heterocycle, alkyl substituted by cycloalkyl; further detail on R4 is given.; R5 = H, halo, cyano, etc.; R6 = H, halo, alkyl, etc.; R7 = H, halo, alkyl, etc.; R11 = H, (un)substituted alkyl, optionally substituted amino by (un)substituted alkyl; R12 = H, (un)substituted alkyl, aryl; R11 and R12 may combine to form cyclic amino group in cooperation with the adjacent nitrogen.] or their pharmaceutically acceptable salts, characterized by reaction of

compds. II [X, Y, R2-R5 = same as above] or active derivs. thereof with NHR11R12 [R11, R12 = same as above], was provided. For example, to a solution of compound III [R = OH; R' = cyclopentyl] (400 mg) in DMF (5.0 mL) was added 1,1'-carbonyldiimidazole (350 mg) at room temperature, the the reaction was stirred at 100 °C for 20 h. The resulting mixture was treated with Et3N (0.2 mL) and glycine Et ester hydrochloride (180 mg) at room temperature for 5 h to give compound III [R = NHCH2CO2Et; R' = cyclopentyl].


In platelet aggregation inhibition assays, compound III [R = NHCH2CH2P(:O)(OH)2; R' = 2,2-dimethyl-1,3-dioxan-5-yl] exhibited the activity of 92%.

ACCESSION NUMBER: 2006:882644 CAPLUS
 DOCUMENT NUMBER: 145:292885
 TITLE: Quinolone and related compounds as platelet aggregation inhibitors, and process for the preparation thereof
 INVENTOR(S): Watanuki, Susumu; Koga, Yuji; Moritomo, Hiroyuki; Tsukamoto, Kazunari; Kaga, Daisuke; Okuda, Takao; Hirayama, Fukushi; Moritani, Yumiko; Takahashi, Atsushi
 PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 95pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006225379	A	20060831	JP 2006-9367	20060118
PRIORITY APPLN. INFO.:			JP 2005-12618	A 20050120
OTHER SOURCE(S):	MARPAT 145:292885			
IT 836613-50-4P	836617-05-1P	836617-06-2P		
836617-18-6P	836617-19-7P			
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)	(preparation of quinolone and related compds. as platelet aggregation inhibitors)			
RN 836613-50-4	CAPLUS			
CN Glycine, N-[(7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)				




RN 836617-05-1 CAPLUS
 CN Glycine, N-[(1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 836617-06-2 CAPLUS

CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 836617-18-6 CAPLUS

CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 836617-19-7 CAPLUS

CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 836621-98-8P, tert-Butyl [[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl]amino]acetate


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinolone and related compds. as platelet aggregation

inhibitors)


RN 836621-98-8 CAPLUS

CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinoliny]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




=> d 14 2-7 abs ibib hitstr

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I




II

AB Title compds. I [X = CR7, N; Y = CR6, N; R11 = H, (un)substituted alkyl, optionally substituted amino by (un)substituted alkyl; R12 = H, (un)substituted alkyl, aryl; R11 and R12 may combine to form a (un)substituted cyclic amino group in cooperation with the adjacent nitrogen; R2 = (un)substituted alkyl, cycloalkyl, aryl, etc.; R3 = halo, alkyl, -O-alkyl; R4 = (un)substituted cycloalkyl, non aromatic heterocycle, alkyl substituted by cycloalkyl; further detail on R4 is given.; R5 = H, halo, cyano, etc.; R6 = H, halo, alkyl, etc.; R7 = H, halo, alkyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, Pd/C catalyzed debenzylation of compound II [R = OCH2Ph] under H2 afforded compound II [R = OH]. In platelet aggregation inhibition assays, compound II [R =


OH] exhibited the activity of 92%.

ACCESSION NUMBER: 2006:882641 CAPLUS
DOCUMENT NUMBER: 145:292884
TITLE: Preparation of quinolone derivatives as platelet aggregation inhibitors
INVENTOR(S): Watanuki, Susumu; Koga, Yuji; Moritomo, Hiroyuki; Tsukamoto, Kazunari; Kaga, Daisuke; Okuda, Takao; Hirayama, Fukushi; Moritani, Yumiko; Takasaki, Atsushi
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 95pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006225378	A	20060831	JP 2006-9349	20060118
PRIORITY APPLN. INFO.:			JP 2005-12561	A 20050120
OTHER SOURCE(S):	MARPAT 145:292884			
IT 836613-50-4P	836617-05-1P	836617-06-2P		
836617-18-6P	836617-19-7P			
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
RN 836613-50-4	CAPLUS			
CN Glycine, N-[(7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinoliny]carbonyl]- (9CI) (CA INDEX NAME)				




RN 836617-05-1 CAPLUS
CN Glycine, N-[(1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinoliny]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 836617-06-2 CAPLUS
CN Glycine, N-[(7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinoliny]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 836617-18-6 CAPLUS
 CN Glycine, N-[(1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 836617-19-7 CAPLUS
 CN Glycine, N-[(7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)




IT 836621-98-8P, tert-Butyl {[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino]acetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of quinolone derivs. as platelet aggregation inhibitors)
 RN 836621-98-8 CAPLUS
 CN Glycine, N-[(7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





I



II

AB The title compds. (I) and pharmaceutically acceptable salts thereof characterized by each having an amide group at the 3-position which is substituted with a substituent having a carboxylate ester, phosphate ester, sulfate ester or the like, and an amino group at the 7-position which is substituted with a substituent having a ring structure [Y = C-R6; R6 = H, halo, lower alkyl, halo-lower alkyl; R2 = each (un)substituted lower alkyl, cycloalkyl, aryl, or heterocyclyl; R3 = halo; R5 = H, HO, halo; R11 = H, lower alkyl or lower alkyl-amino wherein lower alkyl is optionally substituted; R12 = (un)substituted lower alkyl] are prepared. These compds. have excellent P2Y12 (adenine diphosphate receptor) inhibitory effect and platelet agglutination inhibitory effect and consequently are useful as platelet agglutination inhibitors. Thus, hydrogenolysis of [2-((7-(Cyclohexylamino)-1-(2,2-dimethyl-1,3-dioxan-5-yl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl)carbonyl)aminoethyl]phosphonic acid dibenzyl ester over 10% Pd-C in MeOH under hydrogen atmospheric for 3 h gave [2-((7-(Cyclohexylamino)-1-(2,2-dimethyl-1,3-dioxan-5-yl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl)carbonyl)aminoethyl]phosphonic acid (II). II inhibited ADP-induced aggregation of human blood platelet by 92% at 10 μ M and the binding of [3H]-2-MeS-ADP to human P2Y12 by 96% at 30 nM.

ACCESSION NUMBER: 2006:733081 CAPLUS

DOCUMENT NUMBER: 145:188746

TITLE: Preparation of 4-quinolone-3-carboxamide derivatives and salts thereof as platelet aggregation inhibitors

INVENTOR(S): Koga, Yuji; Okuda, Takao; Hirabayashi, Ryoji; Fujiyasu, Jiro; Miyazaki, Takehiro; Watanuki, Susumu; Hirayama, Fukushi; Moritani, Yumiko; Takasaki, Jun

PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan

SOURCE: PCT Int. Appl., 150 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006077851	A1	20060727	WO 2006-JP300590	20060118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2005-12715 A 20050120

OTHER SOURCE(S): MARPAT 145:188746


IT 836621-98-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 4-oxoquinoline-3-carboxamide derivs. and salts thereof as platelet aggregation inhibitors and P2Y12 receptor inhibitors)

RN 836621-98-8 CAPLUS

CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinoliny]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 836613-50-4P, [[[7-[(Cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl]amino]acetic acid

836617-05-1P 836617-06-2P 836617-18-6P


836617-19-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 4-oxoquinoline-3-carboxamide derivs. and salts thereof as platelet aggregation inhibitors and P2Y12 receptor inhibitors)

RN 836613-50-4 CAPLUS


CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinoliny]carbonyl]- (9CI) (CA INDEX NAME)




RN 836617-05-1 CAPLUS
CN Glycine, N-[(1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 836617-06-2 CAPLUS
CN Glycine, N-[(7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 836617-18-6 CAPLUS
CN Glycine, N-[(1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 836617-19-7 CAPLUS
CN Glycine, N-[(7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted (hetero)aryl which may be monocyclic or fused with a single or multiple ring and optionally containing a heteroatom; R5 = H, OR2, alkyl, alkenyl, etc.] or II [V, A, X, Z, and U are as defined above; W = (un)substituted 1,2-benzo, pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful in screening and for inducing apoptosis. Over forty synthetic examples showed the synthesis of intermediates and target compds. E.g., a multi-step synthesis of the amide III, starting from 2,3,4,5-tetrafluorobenzoic acid, was given. The title compds. were tested in various tests. For example, they were tested in a stop assay, a high throughput, first-pass screen detecting drugs that bind to and stabilize the target G-quadruplex. E.g., the compound III exhibits approx. 400x selectivity for the c-Myc quadruplex relative to pUC 18 plasmid DNA. III was also tested for antitumor activity (biol. data given). The pharmaceutical composition comprising the compds. I or II is disclosed.

ACCESSION NUMBER: 2006:120542 CAPLUS
DOCUMENT NUMBER: 144:212787
TITLE: Preparation of substituted quinobenzoxazine analogs as antitumor agents
INVENTOR(S): Whitten, Jeffrey P.; Schwaebel, Michael; Siddiqui-Jain, Adam; Moran, Terence
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 558 pp., Cont.-in-part of U.S. Ser. No. 903,975.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006029950	A1	20060209	US 2005-106909	20050415
US 7141565	B1	20061128	US 2004-821243	20040407
US 2005085468	A1	20050421	US 2004-903975	20040730
AU 2005325210	A1	20060727	AU 2005-325210	20050729
CA 2575547	A1	20060727	CA 2005-2575547	20050729
WO 2006078317	A1	20060727	WO 2005-US26977	20050729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

EP 1773346 A1 20070418 EP 2005-856890 20050729

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: US 2003-461271P P 20030407
US 2003-463171P P 20030415
US 2003-519535P P 20031112
US 2003-532727P P 20031223
US 2004-821243 A2 20040407
US 2004-903975 A2 20040730
US 2005-106909 A 20050415
WO 2005-US26977 W 20050729

OTHER SOURCE(S): MARPAT 144:212787

IT 783361-99-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinobenzoxazine analogs as antitumor agents)

RN 783361-99-9 CAPLUS

CN L-Serine, N-[(5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted 1,2-benzo,

pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful for ameliorating a cell disorder such as cancer. Forty-six synthetic examples showed the synthesis of intermediates. E.g., a 4-step synthesis of the fluoroacid II, starting from potassium Et malonate and 2,3,4,5-tetrafluorobenzoyl chloride, was given. Such prepared fluoroacids were reacted with amines to provide compds. I which were then tested in MTS assay and for inhibition of c-myc mRNA. E.g., the compound III showed 50% inhibition of c-myc mRNA levels at 4 μ M. The compds. I were tested for antitumor activity in mice (biol. data given for representative compds. I). The compds. I were also claimed as useful for ameliorating a microbial infection.

ACCESSION NUMBER: 2005:349002 CAPLUS
 DOCUMENT NUMBER: 142:373851
 TITLE: Preparation of substituted quinobenzoxazine analogs as antitumor agents
 INVENTOR(S): Whitten, Jeffrey P.; Schwaebe, Michael; Siddiqui-Jain, Adam; Moran, Terence
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 453 pp., Cont.-in-part of U.S. Ser. No. 821,243.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005085468	A1	20050421	US 2004-903975	20040730
US 7141565	B1	20061128	US 2004-821243	20040407
US 2006029950	A1	20060209	US 2005-106909	20050415
AU 2005325210	A1	20060727	AU 2005-325210	20050729
CA 2575547	A1	20060727	CA 2005-2575547	20050729
WO 2006078317	A1	20060727	WO 2005-US26977	20050729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1773346	A1	20070418	EP 2005-856890	20050729
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2006229303	A1	20061012	US 2006-390810	20060328
US 2007043039	A1	20070222	US 2006-431602	20060510
PRIORITY APPLN. INFO.:				
US 2003-461271P P 20030407				
US 2003-463171P P 20030415				
US 2003-519535P P 20031112				
US 2003-532727P P 20031223				
US 2004-821243 A2 20040407				
US 2004-903975 A2 20040730				
US 2005-106909 A 20050415				
WO 2005-US26977 W 20050729				

OTHER SOURCE(S): MARPAT 142:373851
 IT 783361-99-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted quinobenzoxazine analogs as antitumor agents)


RN 783361-99-9 CAPLUS

CN L-Serine, N-[[5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB Title compds. I [X = CR7, N; Y = CR6, N; R11 = H, (un)substituted alkyl, etc.; R12 = H, (un)substituted alkyl, etc.; R2 = (un)substituted alkyl, etc.; R3 = halo, etc.; R4 = (un)substituted cycloalkyl, etc.; R5 = H, halo, etc.; R6 = H, halo, etc.; R7 = H, halo, etc.] were prepared. For example, hydrogenolysis of compound II [A = OCH2Ph] afforded compound II [A = OH]. In platelet aggregation inhibition assays, compound II [A = OH] exhibited inhibition activity of 92%. Compds. I are claimed useful as platelet aggregation inhibitors, P2Y12 inhibitors.

ACCESSION NUMBER: 2005:99478 CAPLUS

DOCUMENT NUMBER: 142:197896

TITLE: Preparation of quinolone derivatives as platelet aggregation inhibitors

INVENTOR(S): Watanuki, Susumu; Koga, Yuji; Moritomo, Hiroyuki; Tsukamoto, Issei; Kaga, Daisuke; Okuda, Takao; Hirayama, Fukushi; Moritani, Yumiko; Takasaki, Jun

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009971	A1	20050203	WO 2004-JP10781	20040722
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005053903	A	20050303	JP 2004-212326	20040720
CA 2530352	A1	20050203	CA 2004-2530352	20040722
EP 1650192	A1	20060426	EP 2004-748045	20040722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1826321	A	20060830	CN 2004-80021187	20040722
US 2006148806	A1	20060706	US 2005-562128	20051223
PRIORITY APPLN. INFO.:			JP 2003-278852	A 20030724
			WO 2004-JP10781	W 20040722

OTHER SOURCE(S): MARPAT 142:197896

IT 836613-50-4P 836617-05-1P 836617-06-2P


836617-18-6P 836617-19-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolone derivs. as platelet aggregation inhibitors, P2Y12 inhibitors)


RN 836613-50-4 CAPLUS

CN Glycine, N-[(7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinoliny]carbonyl]- (9CI) (CA INDEX NAME)




RN 836617-05-1 CAPLUS

CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 836617-06-2 CAPLUS

CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 836617-18-6 CAPLUS

CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 836617-19-7 CAPLUS

CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 836621-98-8P, tert-Butyl [([7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl)amino]acetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of quinolone derivs. as platelet aggregation inhibitors, P2Y12 inhibitors)
 RN 836621-98-8 CAPLUS
 CN Glycine, N-[(7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted 1,2-benzo, pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful for ameliorating a cell disorder such as cancer. Forty-six synthetic examples showed the synthesis of intermediates. E.g., a 4-step synthesis of the fluoroacid II, starting from potassium Et malonate and 2,3,4,5-tetrafluorobenzoyl chloride, was given. Such prepared fluoroacids were reacted with amines to provide compds. I which were then tested in MTS assay and for inhibition of c-myc mRNA. E.g., the compound III showed 50% inhibition of c-myc mRNA levels at 4 μ M. The compds. I were tested for antitumor activity in mice (biol. data given for representative compds. I). The compds. I were also claimed as useful for ameliorating a microbial infection.


ACCESSION NUMBER: 2004:902098 CAPLUS
 DOCUMENT NUMBER: 141:395565

TITLE: Preparation of substituted quinobenzoxazine analogs as antitumor agents
 INVENTOR(S): Whitten, Jeffrey P.; Schwaebbe, Michael; Siddiqui-Jain, Adam; Moran, Terrance
 PATENT ASSIGNEE(S): Cyclene Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 438 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091504	A2	20041028	WO 2004-US11108	20040407
WO 2004091504	A3	20060105		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004229489	A1	20041028	AU 2004-229489	20040407
CA 2521810	A1	20041028	CA 2004-2521810	20040407
EP 1610759	A2	20060104	EP 2004-759406	20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 200409105	A	20060425	BR 2004-9105	20040407
CN 1809572	A	20060726	CN 2004-80014351	20040407
JP 2006522827	T	20061005	JP 2006-509898	20040407
NO 2005004669	A	20051114	NO 2005-4669	20051011
PRIORITY APPLN. INFO.:				
			US 2003-461271P	P 20030407
			US 2003-463171P	P 20030415
			US 2003-519535P	P 20031112
			US 2003-532727P	P 20031223
			WO 2004-US11108	W 20040407

OTHER SOURCE(S): MARPAT 141:395565
 IT 783361-99-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).
 (preparation of substituted quinobenzoxazine analogs as antitumor agents)
 RN 783361-99-9 CAPLUS
 CN L-Serine, N-[[5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>
Connection closed by remote host